An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study

NCT05299931 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Ustekinumab

Sponsor

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

Collaborators

[object Object]